Posts tagged “GSK”
Siemens, GSK joint venture team for personalized diagnostic drug tests
An HIV/AIDS treatment developed by GlaxoSmithKline is now being studied with Siemens to develop companion diagnostics that doctors can use to select patients appropriate for the treatment.
Tale of two drug giants: GSK's pipeline full, AstraZeneca's dwindles
Analysis: While AstraZeneca cuts, GSK is putting itself in a position to discover, develop and position for approval of a wider array of potential drug candidates. It's a strategy that should pay off in the best of times, and the worst of times.
Drug research
GSK is back in the black but reason to cheer?
Chief Executive Officer Andrew Witty used the quarterly performance to tout his performance as CEO and multiple advances in the drug giant's product pipeline. However, two analysts are cautious about the news.
GSK Headquarters
GSK state of the company 2012: From headwinds to tailwinds, says CEO
Andrew Witty, in his fourth year as chief executive officer at GlaxoSmithKline, provides a state of the company overview as GSK reports a return to profitability in the fourth quarter. "For us the headwinds that we've faced for the last four or five years are diminishing, and we've been building more of our own tailwinds in terms of our R&D portfolio and the investment we've been making in our new growth business like emerging markets, consumer, the vaccine business," he says. Witty is also especially excited about progress in R&D.
Andrew Witty
GSK puts four clinical trials on hold, development partner says
Anacor Pharmaceuticals discloses that GlaxoSmithKline "voluntarily passed" enrollment in the trials due to a "recently identified microbiological finding" in some patients.
GSK agrees to settle 20,000 Avandia drug cases
The pharmaceutical giant reached the deal last month as part of the company's efforts to resolve legal issues over the last decade surrounding the former blockbuster type 2 diabetes drug.
Red Hat Enterprise Linux 'life' extension; GSK eyes Turkish firm; a Cree downgrade; Amazon misses; LightSquared deadline; Samsung-Apple fight; Sony's new CEO
Inside the Bulldog blog: Red Hat is extending the life space on its Enterprise Linux; GSK, Pfizer may buy Turkish drug maker; Cree stock is cut; Amazon misses by $1 billion; Sprint gives LightSquared extension for satellite service; Samsung setbacks in Apple patent fight; Sony names a new CEO.
Business a key in GSK, big pharma drive against 'neglected' diseases
Analysis: Pharma companies should be lauded for partnering on a renewed focus on neglected diseases. But don't mistake their actions as completely altruistic. These changes are happening because of fundamental shifts in the economics of the pharmaceutical industry.
Andrew Witty
GSK, other drug firms join Gates Foundation to combat 'neglected' diseases
Partners in the initiative, including 13 manufacturers of drugs or medical equipment, pledged to come up with new products and infrastructure to improve the lives of the 1.4 billion people affected by 10 illnesses such as visceral leishmaniasis, river blindness and lymphatic filariasis.
Bill and Melinda Gates
Google Maps alerts; VMware counters Red Hat; Angry Birds on Facebook; GSK's angry partner; NEC cutting jobs;
In the Bulldog: Google is adding public alerts to its Maps service; VMware launches virtualization marketplace; Angry Birds to hit Facebook on Valentine's Day; Xenoport says GSK violated deal; Lenovo partner NEC cutting 10,000 jobs.
GSK refuses to give up on Avodart as prostate cancer treatment
A GSK-funded study published in The Lancet backs the drug, but an editorial in the same publication disagrees.
Testing at Olympics: GSK touts 'Journey of a Sample'
The drug giant will provide testing for athletes at the 2012 Olympics in London as well as for the Paralympic Games. In a video, GSK touts the testing technology.
Study: GSK, Roche breast cancer drugs work best together
The findings could boost the treatment options for patients and the marketing potential for GSK's Tykerb, which falls well short of the Roche drug Herceptin in terms of global sales.
GSK bolsters its cancer drug discovery efforts
SuperGen transfers its Climb platform technology, which screens libraries of compounds with computational chemistry in order to speed up the drug discovery process, to GSK.
GSK appeals Argentina clinical trial fines, denies role in deaths
An Argentine judge fined GSK some $93,000 for problems with recruitment of some children for the clinical trial involving the pneumococcal vaccine Synflorix. Two clinical trials investigators also were fined, according to the life science news site PharmaTimes.
